Argenx Se (ARGX) Income from Discontinued Operations (2018 - 2025)
Argenx Se (ARGX) posted Income from Discontinued Operations of 129656000.0 for Q4 2025, up 410.22% on a QoQ basis from 41795000.0 in Q3 2025, and down 81.15% year-over-year from 687652000.0 in Q4 2024.
Argenx Se (ARGX) Income from Discontinued Operations (2018 - 2025) Analysis & Trends
Argenx Se's Income from Discontinued Operations history runs 6 years deep, the most recent figure standing at 129656000.0 for Q4 2025.
- Quarterly Income from Discontinued Operations fell 81.15% year-over-year to 129656000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 96510000.0 (down 87.1% YoY) and the FY2025 annual result came in at 13428000.0, down 98.2% from the prior year.
- Income from Discontinued Operations was 129656000.0 for Q4 2025 at Argenx Se, up from 41795000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 687652000.0 in Q4 2024 and bottomed at 41795000.0 in Q3 2025.
- A 5-year average of 49074722.22 and a median of 6522000.0 in 2021 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2023 — Income from Discontinued Operations sank 1547.39% — and 2024, when it jumped 1909.9%.
- Argenx Se's Income from Discontinued Operations stood at 7062000.0 in 2021, then sank by 62.83% to 2625000.0 in 2022, then sank by 1547.39% to 37994000.0 in 2023, then soared by 1909.9% to 687652000.0 in 2024, then tumbled by 81.15% to 129656000.0 in 2025.
- Business Quant data shows ARGX's Income from Discontinued Operations at 129656000.0 in Q4 2025, 41795000.0 in Q3 2025, and 41541000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 129.66 Mn |
| Sep 30, 2025 | -41.80 Mn |
| Jun 30, 2025 | 41.54 Mn |
| Mar 31, 2025 | -32.89 Mn |
| Dec 31, 2024 | 687.65 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 44.07 Mn |
| Mar 31, 2024 | 12.75 Mn |
| Dec 31, 2023 | -37.99 Mn |
| Sep 30, 2023 | 10.64 Mn |
| Jun 30, 2023 | -10.51 Mn |
| Mar 31, 2023 | 47.31 Mn |
| Dec 31, 2022 | 2.63 Mn |
| Sep 30, 2022 | 5.98 Mn |
| Jun 30, 2022 | 8.23 Mn |
| Mar 31, 2022 | 2.89 Mn |
| Dec 31, 2021 | 7.06 Mn |
| Sep 30, 2021 | 2.75 Mn |
| Sep 30, 2018 | 1,163.13 |